We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Events

02 Jun 2026 - 04 Jun 2026
17 Jun 2026 - 19 Jun 2026
05 Oct 2026 - 06 Oct 2026

Common Pain Relievers Reduce Breast Cancer Risk

By HospiMedica staff writers
Posted on 16 Apr 2003
A study has concluded that weekly doses of nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen and aspirin can inhibit the formation and growth of breast cancer. More...
The results were reported in the Proceedings for the 94th Annual Meeting of the American Association for Cancer Research (AACR) in Philadelphia (PA, USA).

The study showed that women taking two or more NSAIDs a per week for five to nine years reduced their risk of breast cancer by 21%. Extending use to ten or more years resulted in an even greater reduction of 28%. The probability of developing breast cancer was estimated and adjusted for age and other risk factors (body mass, estrogen use, exercise, family history). Researchers noted that ibuprofen was more effective than aspirin (49% vs 21%), and regular use of low-dose aspirin had no effect.

The primary mechanism of action of these drugs is the inhibition of COX-2 , which is over-expressed in most human breast cancers. The data were taken from the Women's Health Initiative (WHI) Observational Study of the US National Cancer Institute, involving 80,741 postmenopausal women between 50 and 79 years of age with no reported history of any cancer other than nonmelanoma skin cancer.

"These results suggest that even women at high risk for breast cancer may be protected by taking NSAIDs,” explained Randall Harris, M.D., Ph.D., lead investigator and professor in the division of epidemiology and biometrics at Ohio State University (Columbus, USA). "However, before usage guidelines for NSAIDs can be implemented, additional studies are needed.”

Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Gold Member
Handheld Blood Glucose Analyzer
STAT-Site
New
Creatinine/eGFR Meter
StatSensor® Creatinine/eGFR Meter
New
Medical Adhesive
MED 5570U
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The Elyra TFL System uses thulium fiber laser technology for efficient stone dusting and reduced stone migration, with an air-cooled design for quieter, more compact operation (photo courtesy of BD

BD Launches Elyra Laser Platform for Kidney Stone and Soft Tissue Procedures

BD (Becton, Dickinson and Company) has introduced the Elyra Thulium Fiber Laser (TFL) System, an advanced laser platform developed to complete its kidney stone care portfolio for urology teams.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.